Navigation Links
New Survey Reveals High Expectations for Popular Aesthetic Injections
Date:7/7/2009

SCOTTSDALE, Ariz., July 7 /PRNewswire/ -- Americans aren't willing to give up aesthetic injections and interest is growing, whether as a means to stay competitive in today's job market or simply to maintain a youthful image, the demand and want is strong. At the time of a recent Kelton Research* survey more than 40 percent of respondents were interested in receiving aesthetic botulinum toxin injections within the next six months.(1)

Despite clear interest, many expressed reluctance to having a botulinum toxin injection. In fact, one-third of those who had not yet received the treatment were worried that it would prevent them from being able to make natural facial expressions.(1)

Sixty-three percent of survey respondents who would ever consider receiving botulinum toxin injections cited that a guarantee of natural-looking results would influence their decision, demonstrating a desire for retaining a natural-looking face, and more natural-looking expressions following injection.(1) Other top factors included more affordable costs, longer-lasting and faster-acting results.(2)

The poll found that of the respondents who had never undergone botulinum toxin injections, 36% said that their concern about no longer having a natural look had prevented them from receiving the treatment in the past.(1) Almost 60 percent of those surveyed who had not ever received an injection stated that they'd be likely to if the cost of treatment was more affordable.(1) And, of the respondents who had botulinum toxin injections, three in ten reported not seeing noticeable results for at least a week(1) and thirty percent of polled respondents said that having immediate results, such as within 24-48 hours, would positively influence their decision to undergo treatment.(2)

According to Florida dermatologist Dr. Susan Weinkle, patients want value and rapid results at a fair price. "My patients are looking for a treatment that will not make them look obvious or overdone and they want these natural looking results fast."

They are in luck: after extensive testing and clinical results, a new Botulinum Toxin A is now on the market. Dysport(TM) has been approved by the FDA for use in the United States for the temporary improvement in the appearance of moderate to severe glabellar lines - the vertical lines between the eyebrows - in adult men and women 65 or younger.

The benefits of Dysport(TM) include:

  • Duration - results lasting up to four months
  • Demonstrated efficacy with four repeat treatments (proving results following each treatment)
  • Demonstrated safety with 12 repeat treatments
  • No evidence of neutralizing antibodies
  • Clinical trials included both subjects who have and have not previously been treated with a Botulinum Toxin. There was no difference in results among the two groups
  • Large patient population - 4,800 treatments in 2,900 patients (with an ethnically diverse population)

*About the 2009 Botulinum Toxin survey:

Sample: 600 U.S. adults ages 25-60 with a household income of $50,000 or more, including 570 females and 300 botulinum toxin users and 300 aware of at least one nonsurgical aesthetic procedure or treatment.(2)

References:

1. Kelton Research. Botulinum Toxin Survey NewsWorthy Analysis. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.

2. Kelton Research. Botulinum Toxin Survey Topline Report. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.

Important Safety Information

Dysport(TM) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in appearance of moderate to

severe glabellar lines associated with procerus and corrugator muscle activity in adult patients.

Botulinum toxin effects may spread beyond the site of local injection to produce systemic symptoms of botulism such as swallowing and breathing difficulties that can occur within hours to weeks of injection. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults, particularly in those patents who have underlying conditions that would predispose them to these symptoms. In clinical trials, the most frequently reported adverse effects (>2%) are headache, nasopharyngitis and upper respiratory tract infection.

Dysport(TM) is not recommended for children or pregnant women. Re-treatment with Dysport(TM) should be administered no more than every three months.


'/>"/>
SOURCE Medicis Aesthetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NEUTROGENA(R) and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection
2. National Survey Shows 70% of Women Have Experienced a Sexual Health Issue
3. CED/Zogby Release Survey of Business Perspectives on Healthcare Reform
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. SouthWest Benefits Association Survey Finds Employers Continue to Focus on Health and Wellness during Economic Downturn
6. Innoventz Certified to Score Both the SF-36v2 and SF-12v2 Health Surveys
7. Snoring Isn't Sexy, LLC Launches Survey to Determine Extent of Drowsy Drivers on Land, Sea and In The Air
8. CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting
9. ZoneDiet.com Survey Reveals That Body Insecurity Prevents Nearly Half (49%) of Americans From Engaging in Summer Activities
10. Recent Survey Suggests Complications with Permanent Fillers
11. URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... ... August 24, 2017 , ... Lori ... the development and advances in Desensitization therapy to improve the outcomes of organ ... about his remarkable journey of his 25 years of research in developing therapies ...
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home ... have a condition that needs further monitoring such as surgery, stroke, heart attack ... stable, such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. ...
(Date:8/23/2017)... ... 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs and ... community organization for people with special needs. The group, the Special Needs Alliance for ... of New Jersey – but the first in the entire country! , SNAP was ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... ... Awards have announced the winners of the Best of the IBA Awards in The 2017 ... in the 2017 IBAs were not able to apply for the Best of the IBA ... awards won in the IBAs with a Gold Stevie win counting for three points, a ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017   Mostyn Law and Gulf Coast Regional Blood ... . The Mostyn Law family has had 3 ... is why Mostyn Law is partnering with Gulf Coast ... its appreciation. Blood supplies are running low. Gulf Coast ... hospital needs in August. That is why the blood center reached ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: